atazanavir viatris
viatris limited - atazanavir sulfate 170.85mg equivalent to atazanavir 150mg; atazanavir sulfate 170.85mg equivalent to atazanavir 150mg - capsule - 150 mg - active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: crospovidone gelatin iron oxide red lactose monohydrate magnesium stearate patent blue v purified water tekprint black sw-9008 titanium dioxide active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: brilliant blue fcf crospovidone erythrosine gelatin iron oxide yellow lactose monohydrate magnesium stearate purified water titanium dioxide - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.
atazanavir cipla atazanavir 150 mg capsule bottle pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
atazanavir cipla atazanavir 150 mg capsule blister pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
cipla atazanavir atazanavir 150 mg capsule bottle pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
cipla atazanavir atazanavir 150 mg capsule blister pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
zanavir ca atazanavir 150 mg capsule bottle pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
zanavir ca atazanavir 150 mg capsule blister pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
apo-atazanavir atazanavir 150 mg (as sulfate) capsule bottle
arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: magnesium stearate; sodium starch glycollate type a; purified water; hydrophobic colloidal silica anhydrous; lactose monohydrate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies
apo-atazanavir atazanavir 150 mg (as sulfate) capsule blister pack
arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; purified water; lactose monohydrate; sodium starch glycollate type a; magnesium stearate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies
atazanavir apotex atazanavir 150 mg (as sulfate) capsule bottle
arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule - excipient ingredients: purified water; hydrophobic colloidal silica anhydrous; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; gelatin - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies